A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

NCT04557150 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
225
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Hoffmann-La Roche